KOHALA COAST — Big Island community members have teamed with the Myotonic Dystrophy Foundation (MDF) to organize E ha ‘awi i ka mana’ olana (to give hope), a weekend of events and activities set for ...
$470,000 raised for Myotonic Dystrophy Foundation: Waimea resident helps organize two-day fundraiser
KOHALA COAST — Supporters from Hawaii and the mainland came together Nov. 9 and 10 to attend E ha ‘awi i ka mana’ olana (to give hope), a weekend of events and activities on the Kohala Coast to ...
SAN DIEGO, Aug. 31, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ...
News-Medical.Net on MSN
Over-contracted gut muscles drive gastrointestinal symptoms in myotonic dystrophy
Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people.
The compound called Cugamycin works by recognizing toxic RNA repeats and destroying the garbled gene transcript. People diagnosed with myotonic dystrophy type 1 have difficulty unclenching muscles due ...
NOTE: Occasionally, a lobbying client may refer to a bill number from a previous Congress, either in error or because they are lobbying on a bill that has not yet ...
LONDON and PHILADELPHIA, Sept. 16, 2019 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, childhood onset neurogenetic disorders with ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced its ...
People diagnosed with myotonic dystrophy type 1 have difficulty unclenching muscles due to a genetic defect that generates toxic material within their cells. There is currently no treatment. In a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback